Geron Corp (GERN) option IV into FDA Oncologic Drugs Advisory Committee meeting
March 14, 2024 5:10 AM
Geron Corp (NASDAQ: GERN) 30-day option implied volatility is at 265; compared to its 52-week range of 56 to 220 into FDA Oncologic Drugs Advisory Committee meeting.
